The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34739066.
- Also identified by DOI 10.1001/jamanetworkopen.2021.33132 and PMC identifier 8571658.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study investigates the association between low levels of <i>ERBB2</i> expression and progression-free survival among patients with HR+/<i>ERBB2</i>− metastatic breast cancer treated with CDK4/6 inhibitors.
Medical subject headings
- Breast Neoplasms
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Erb-b2 Receptor Tyrosine Kinases